Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
slumberBUMP⢠was invented by Dr. Shad Morris, DMD from Premier Sleep Solutions. ...
slumberBUMP⢠was invented by Dr. Shad Morris,...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
Agios is a biopharmaceutical company passionately committed to applying our scient...
Agios is a biopharmaceutical company passionate...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinicalâstage biopharmaceutical c...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...
Join the National Investor Network and get the latest information with your interests in mind.